Möchten Sie immer auf dem neuesten Stand bleiben?

Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.

Beim Leserkonto Anmelden Leserkonto Erstellen

24. August 2021 15:44 ET | Quelle: The Insight Partners

TMS (Transcranial Magnetic Stimulator) Market ($2.02Bn by 2028) Growth Forecast at 8.8% CAGR During (2021-2028) - COVID-19 Impact and Global Analysis by TheInsightPartners.com

New York, Aug. 25, 2021 (GLOBE NEWSWIRE) -- Transcranial Magnetic Stimulator (TMS) Market: Key InsightsAccording to our latest study on “Transcranial Magnetic Stimulator (TMS) Market Forecast to...
19. August 2021 18:15 ET | Quelle: The Rosen Law Firm PA

ANVS BREAKING ALERT: ROSEN, LEADING TRIAL ATTORNEYS, Encourages Annovis Bio, Inc. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action – ANVS

NEW YORK, Aug. 19, 2021 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of...
10. August 2021 07:00 ET | Quelle: BioXcel Therapeutics

BioXcel Therapeutics Reports Second Quarter 2021 Financial Results and Recent Operational Highlights

Phase 3 study of BXCL501 for the acute treatment of agitation associated with dementia expected to begin in Q4 2021 PDUFA date of January 5, 2022 assigned to BXCL501 NDA for the acute treatment of...
28. Juli 2021 07:00 ET | Quelle: BioXcel Therapeutics

BioXcel Therapeutics to Report Second Quarter 2021 Financial Results on August 10, 2021

NEW HAVEN, Conn., July 28, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (“BioXcel” or the “Company”) (NASDAQ: BTAI), a clinical-stage biopharmaceutical company utilizing artificial...
22. Juli 2021 12:10 ET | Quelle: AB Science

AB Science annonce qu’un résumé de son étude de phase 3 dans la maladie d’Alzheimer a été sélectionné pour une présentation orale à la Alzheimer’s Association International Conference (AAIC)

COMMUNIQUE DE PRESSE AB SCIENCE PRESENTERA LES RESULTATS DE SON ETUDE DE PHASE 3 AB09004 DANS LES FORMES LEGERES A MODEREES DE LA MALADIE D’ALZHEIMER LORS DE LA PLUS GRANDE CONFERENCE MONDIALE SUR LA...
22. Juli 2021 12:10 ET | Quelle: AB Science

AB Science today announced that an abstract reporting results from its Phase 3 AB09004 study on Alzheimer’s disease has been selected for an oral presentation at the annual Alzheimer’s Association International Conference (AAIC)

PRESS RELEASE AB SCIENCE TO PRESENT RESULTS FROM ITS PHASE III AB09004 STUDY IN MILD TO MODERATE ALZHEIMER’S DISEASE AT THE WORLD'S LARGEST CONFERENCE FOR ALZHEIMER’S AND DEMENTIA RESEARCH (AAIC...
19. Juli 2021 07:30 ET | Quelle: BioXcel Therapeutics

BioXcel Therapeutics to Present at Canaccord Genuity 41st Annual Growth Conference

NEW HAVEN, Conn., July 19, 2021 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. ("BioXcel" or the "Company") (Nasdaq: BTAI), today announced that Dr. Vimal Mehta, Ph.D., Founder and Chief Executive...
23. Juni 2021 09:19 ET | Quelle: Revera Inc.

Revera debuts Unforgettable Ian’s journey in long term care

Mississauga, Ontario, June 23, 2021 (GLOBE NEWSWIRE) -- Today, Revera, a leader in the senior living sector, is releasing Unforgettable Ian, a film about a remarkable resident at Revera’s Stoneridge...
06. April 2021 08:00 ET | Quelle: Posit Science

$44 Million NIH Grant to See if Dementia Can Be Prevented

SAN FRANCISCO, April 06, 2021 (GLOBE NEWSWIRE) -- Researchers at the University South Florida in Tampa have received a $44.4 million grant from the National Institutes of Health (NIH) for the...
11. März 2021 07:05 ET | Quelle: Annovis Bio, Inc.

Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit

BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual...

Vorherige Seite

Nächste Seite